Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease

Basit Öğe Kaydı
dc.authorid41809en_US
dc.contributor.authorAharoni, Rina
dc.contributor.authorKayhan, Başak
dc.contributor.authorBrenner, Ori
dc.contributor.authorDomev, Hagit
dc.contributor.authorLabunskay, Galya
dc.contributor.authorArnon, Ruth
dc.date.accessioned2017-08-03T11:43:08Z
dc.date.available2017-08-03T11:43:08Z
dc.date.issued2006
dc.departmentİnönü Üniversitesien_US
dc.description.abstractInflammatory bowel disease (IBD) is characterized by detrimental immune reactivity in the gut and imbalance between proinflammatory and anti-inflammatory reactivity. In an attempt to down-regulate colitis, we investigated the effect of the immunomodulator glatiramer acetate (GA, Copaxone, copolymer 1) on two murine models of IBD, chemically induced and spontaneous. Acute experimental colitis of different levels of severity was induced in C57BL/6 mice by dextran sulfate sodium (DSS) administered orally at different concentrations and frequencies. It was manifested in weight loss, intestinal bleeding, and diarrhea, as well as by macroscopic and microscopic colon damage. GA treatment led to amelioration of all of these pathological manifestations, resulting in improved long-term survival. Moreover, even when colitis was induced by three cycles of DSS in this highly susceptible mouse strain, as well as in BALB/c mice that exhibit a chronic disease pattern, a substantial reduction in disease activity and mortality was obtained. GA treatment induced a beneficial effect also in a spontaneous model of colitis developed in the C3H/HeJBir IL-10-deficient mice. The detrimental proinflammatory response manifested by proliferation, tumor necrosis factor- , and interferon- expression was modulated by GA, whereas the regulatory anti-inflammatory transforming growth factor- and IL-10 cytokines response was elevated. This was demonstrated on the level of protein secretion in splenocytes and local mesenteric lymphocytes in response to syngeneic colon extract and in the overall response to anti-CD3, as well as on the level of mRNA expression in the colon.en_US
dc.identifier.citationAharoni, R. Kayhan, B. Brenner, O. Domev, H. Labunskay, G. Arnon, R. (2006). Immunomodulatory Therapeutic Effect of Glatiramer Acetate on Several Murine Models of Inflammatory Bowel Disease. Journal of Pharmacology and Experimental Therapeutics, 318(1), 68–78.en_US
dc.identifier.doi10.1124/jpet.106.103192en_US
dc.identifier.endpage78en_US
dc.identifier.issn0022-3565
dc.identifier.issue1en_US
dc.identifier.startpage68en_US
dc.identifier.urihttp://jpet.aspetjournals.org/cgi/doi/10.1124/jpet.106.103192
dc.identifier.urihttps://hdl.handle.net/11616/7437
dc.identifier.volume318en_US
dc.language.isoenen_US
dc.publisherJournal of Pharmacology and Experimental Therapeuticsen_US
dc.relation.ispartofJournal of Pharmacology and Experimental Therapeuticsen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleImmunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel diseaseen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Makale Dosyası.pdf
Boyut:
866.99 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı Koleksiyonu